Sante: Anpil fanm ap fè fas ak twoub manstriyèl aprè yo fin pran vaksen kont kowona viris la

0 37
Subscribe to our newsletter

Daprè sa Ajans Nasyonal Sekirite Medikaman ak pwodwi sante (ANSM), nan peyi lafrans rapòte, gen anpil fanm ki deja ap fè fas ak twoub manstriyèl aprè enjeksyon vaksen kont kowona viris la. Yon sentom ki valab pou 2 dòz yo, “Moderna” ak “Pfizer”.

Pou dòz “Pfizer” a, yo deja resanse 229 ka twoub manstriyèl. Anpil nan fanm sa yo fè konnen, doulè yo vin pi atwòs epi san koule plis, oubyen li retade.

Pou pote yon limyè sou sa, nan yon entèvyou li bay “Le Parisien”, pwofesè ak jinekològ fransè, Olivier Picone eksplike: “sistèm iminitè a ap travay epi ap sekrete pwoteyin. Men si yo sekrete ak yon nivo ki twò wo, sa kapab deranje kominikasyon ovè a ak aks ipotalamo-ipofizè a, sa koz modifikasyon sik manstriyèl la”.

Yon lòt kote, Victoria Male, ki se yon espesyalis nan iminoloji repwodiksyon, te fè konnen. “Siy chimik ki parèt aprè vaksinasyon an ka afekte selil iminitè yo epi modifye pawa iteris la, se konsa li ka koz sèyman ak avanse dat règ yo”.

Malgre tout revelasyon yo, ekspè yo ki vle rasire yo, konstate pa gen anyen ki grav nan sentom sa yo ki prezante a, pa gen risk fos kouch ak enfètilite.

Subscribe to our newsletter
Subscribe to our newsletter
Sign up here to get the latest news, updates and special offers delivered directly to your inbox.
Subscribe to our newsletter
Sign up here to get the latest news, updates and special offers delivered directly to your inbox.
Subscribe to our newsletter
Sign up here to get the latest news, updates and special offers delivered directly to your inbox.
Subscribe to our newsletter
Subscribe to our newsletter
Sign up here to get the latest news, updates and special offers delivered directly to your inbox.

Laisser un commentaire

Votre adresse email ne sera pas publiée.

Subscribe to our newsletter
Subscribe to our newsletter
Sign up here to get the latest news, updates and special offers delivered directly to your inbox.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More